E23- CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD - Dr. Peter Kertes
The Retina Channel Podcast · Keyvan Koushan
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr. Peter Kertes discusses the publication of the first year results of the CANTREAT study that investigates monthly vs treat-and-extend dosing of ranibizumab for wet AMD.
Full reference:
Kertes, P. J., Galic, I. J., Greve, M., Williams, R. G., Rampakakis, E., Scarino, A., & Sheidow, T. (2019). Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study. Ophthalmology. doi:10.1016/j.ophtha.2019.01.013